Spots Global Cancer Trial Database for her2+
Every month we try and update this database with for her2+ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT05748834 | Breast Cancer | Tucatinib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer | NCT00951665 | Metastatic Brea... | paclitaxel pertuzumab [Per... trastuzumab emt... paclitaxel trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | NCT04120246 | Anatomic Stage ... HER2 Positive B... Metastatic Brea... Refractory Brea... | Alpha-tocophery... Trastuzumab | 18 Years - | Veana Therapeutics | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | NCT03319459 | HER2 Positive G... Colorectal Canc... Head and Neck S... EGFR Positive S... Advanced Solid ... HER2-positive B... Hepatocellular ... Non Small Cell ... Renal Cell Carc... Pancreatic Canc... Melanoma | FATE-NK100 Cetuximab Trastuzumab | 18 Years - | Fate Therapeutics | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer | NCT05592483 | Breast Cancer | None (Observati... | 18 Years - 130 Years | AstraZeneca | |
| Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer | NCT02167854 | Breast Cancer | BYL719 LJM716 TRASTUZUMAB | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies | NCT02238509 | Metastatic Brea... | Lapatinib Trastuzumab | 18 Years - | Consorzio Oncotech | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | NCT00679341 | Breast Cancer | Trastuzumab emt... Trastuzumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| IKS014 in Advanced Solid Tumors That Express HER2 | NCT05872295 | Breast Cancer Gastric Cancer Gastroesophagea... | IKS014 | 18 Years - | Iksuda Therapeutics Ltd. | |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | NCT02213744 | Breast Cancer HER2 Positive B... | MM-302 Gemcitabine Capecitabine Vinorelbine Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| IKS014 in Advanced Solid Tumors That Express HER2 | NCT05872295 | Breast Cancer Gastric Cancer Gastroesophagea... | IKS014 | 18 Years - | Iksuda Therapeutics Ltd. | |
| Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma | NCT02120911 | Esophageal Carc... | Pertuzumab, tra... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | NCT04430738 | Colorectal Carc... Gastric Adenoca... GEJ Adenocarcin... Esophageal Aden... Cholangiocarcin... Gallbladder Car... | tucatinib trastuzumab oxaliplatin leucovorin fluorouracil capecitabine pembrolizumab | 18 Years - | Seagen Inc. | |
| Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | NCT01384253 | Breast Neoplasm... Peritoneal Neop... Ovarian Neoplas... Pancreatic Neop... Stomach Neoplas... | ²¹²Pb-TCMC-Tras... trastuzumab | 19 Years - | Orano Med LLC | |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | NCT04686305 | Locally Advance... | T-DXd Durvalumab Cisplatin Carboplatin Pemetrexed MEDI5752 | 18 Years - | AstraZeneca | |
| Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | NCT00928330 | Metastatic Brea... | GDC-0941 Trastuzumab trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer | NCT01361945 | Breast Cancer Metastatic Brea... HER-2 Positive ... ER Positive Bre... | AUY922 | 18 Years - | Texas Tech University Health Sciences Center, El Paso | |
| Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | NCT03501979 | Metastatic Brea... Leptomeningeal ... | Tucatinib Trastuzumab Capecitabine | 18 Years - | University of Alabama at Birmingham | |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT05748834 | Breast Cancer | Tucatinib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | NCT04120246 | Anatomic Stage ... HER2 Positive B... Metastatic Brea... Refractory Brea... | Alpha-tocophery... Trastuzumab | 18 Years - | Veana Therapeutics | |
| A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain | NCT05892068 | Metastatic Brea... | Tucatinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | NCT01774851 | HER-2 Gene Ampl... Esophagus Cance... Gastroesophagea... Stomach Cancer | MM-111 Paclitaxel Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | NCT00928330 | Metastatic Brea... | GDC-0941 Trastuzumab trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | NCT02593708 | Solid Tumor | Neratinib Paclitaxel Pertuzumab Trastuzumab | 18 Years - | University of California, San Francisco | |
| Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. | NCT04896320 | Breast Cancer S... | Tucatinib | 18 Years - | Providence Health & Services | |
| Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer | NCT02598427 | HER2 Positive U... Asymptomatic or... | Pertuzumab Trastuzumab | 18 Years - | Duke University | |
| Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer | NCT02598427 | HER2 Positive U... Asymptomatic or... | Pertuzumab Trastuzumab | 18 Years - | Duke University | |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | NCT04120246 | Anatomic Stage ... HER2 Positive B... Metastatic Brea... Refractory Brea... | Alpha-tocophery... Trastuzumab | 18 Years - | Veana Therapeutics | |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | NCT02213744 | Breast Cancer HER2 Positive B... | MM-302 Gemcitabine Capecitabine Vinorelbine Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | NCT01774851 | HER-2 Gene Ampl... Esophagus Cance... Gastroesophagea... Stomach Cancer | MM-111 Paclitaxel Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | NCT02593708 | Solid Tumor | Neratinib Paclitaxel Pertuzumab Trastuzumab | 18 Years - | University of California, San Francisco |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
